Seeking to expand its strategic footprint, Regeneron (REGN) Pharmaceuticals will provide access to its technology to a small company that has big hopes of discovering medicines to prevent and treat hearing loss. And in exchange, Regeneron is taking an undisclosed equity stake and is slated to receive royalties from any drugs that might one day reach medicine chests.

The deal with Decibel Therapeutics, a privately held company that was launched two years ago, marks only the second time that Regeneron has reached such an arrangement with a preclinical-stage company to discover and develop medicines. Last year, Regeneron reached a similar arrangement with Adicet Bio to develop immune cell therapeutics, although an equity position was not part of that deal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy